Infant leukemia with KMT2A gene rearrangements represents one of pediatric oncology's most stubborn challenges, with current treatments failing half of affected babies and the cancer frequently invading the central nervous system where it proves nearly impossible to eliminate. This therapeutic gap has profound implications for families facing a diagnosis where time and treatment options are critically limited.
Investigators have now engineered a novel cellular weapon that simultaneously targets two surface proteins—CD19 and CD133—on leukemia cells using modified invariant natural killer T cells rather than conventional CAR-T cells. These dual-targeting CAR-iNKT cells demonstrated superior killing power against KMT2A-rearranged leukemia in laboratory models, effectively clearing cancer from both bone marrow and the protective leptomeningeal space surrounding the brain and spinal cord. The approach eliminated leukemia cells regardless of whether they expressed high or low levels of the target antigens, addressing a key mechanism of treatment resistance.
This advancement builds on decades of CAR-T cell development but represents a fundamental shift toward using innate immune cells that can be manufactured as off-the-shelf products, eliminating the weeks-long delay required to engineer a patient's own T cells. The iNKT cells appear to achieve enhanced tumor killing through upregulation of NKG2D receptors, providing additional anti-cancer mechanisms beyond the engineered CARs. While promising in preclinical models, the approach requires validation in human trials to determine whether this dual-targeting strategy can overcome the notorious treatment resistance of infant leukemia. The potential for ready-to-use immunotherapy could transform care timelines for critically ill infants where every day counts.